NO940266L - Indre strålingsskade - Google Patents

Indre strålingsskade

Info

Publication number
NO940266L
NO940266L NO940266A NO940266A NO940266L NO 940266 L NO940266 L NO 940266L NO 940266 A NO940266 A NO 940266A NO 940266 A NO940266 A NO 940266A NO 940266 L NO940266 L NO 940266L
Authority
NO
Norway
Prior art keywords
radiation damage
internal radiation
dgla
gla
treatment
Prior art date
Application number
NO940266A
Other languages
English (en)
Other versions
NO940266D0 (no
Inventor
David Frederick Horrobin
Catherine Ann Scott
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of NO940266D0 publication Critical patent/NO940266D0/no
Publication of NO940266L publication Critical patent/NO940266L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Skader på indre vev, og da spesielt på det sentrale nervesystemet som en konsekvens av eksponering overfor ioniserende stråling, hindres eller behandles ved å tilføre GLA og/eller DGLA. Medikamenter som inneholder GLA og/eller DGLA for slik behandling eller for profylaktisk behandling, kan videre også inneholde EPA og/eller DHA.
NO940266A 1993-01-26 1994-01-25 Indre strålingsskade NO940266L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939301446A GB9301446D0 (en) 1993-01-26 1993-01-26 Internal radiation damage

Publications (2)

Publication Number Publication Date
NO940266D0 NO940266D0 (no) 1994-01-25
NO940266L true NO940266L (no) 1994-07-27

Family

ID=10729293

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940266A NO940266L (no) 1993-01-26 1994-01-25 Indre strålingsskade

Country Status (12)

Country Link
US (2) US5583159A (no)
EP (1) EP0609064A1 (no)
JP (1) JPH06279277A (no)
KR (1) KR940018089A (no)
CN (1) CN1104496A (no)
AU (1) AU673868B2 (no)
CA (1) CA2114047A1 (no)
GB (1) GB9301446D0 (no)
NO (1) NO940266L (no)
NZ (1) NZ250757A (no)
RU (1) RU94002337A (no)
ZA (1) ZA94392B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9621373D0 (en) * 1996-10-14 1996-12-04 Scotia Holdings Plc Fatty acid treatment
EP1090165A2 (de) * 1998-05-28 2001-04-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Schichtsystem zum korrosionsschutz von leichtmetallen und leichtmetalllegierungen
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US20020188024A1 (en) * 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
WO2002069964A1 (en) 2001-03-05 2002-09-12 Ernest Stephen P Enteral formulation
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
WO2005018632A1 (en) 2003-08-18 2005-03-03 Btg International Limited Treatment of neurodegenerative conditions
US7537572B2 (en) * 2004-10-22 2009-05-26 General Patent, Llc Treatment or pre-treatment for radiation/chemical exposure
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2012087113A1 (en) * 2010-12-24 2012-06-28 N.V. Nutricia Improved nutritional tablet
US20130224281A1 (en) * 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US8728546B1 (en) 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
WO2015071766A1 (en) 2013-11-15 2015-05-21 Dignity Sciences Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
JP2017516823A (ja) 2014-06-04 2017-06-22 ディグニティ サイエンシス リミテッド Ｄｇｌａを含む薬学的組成物及びその使用
JP2018524274A (ja) 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
CN112245420A (zh) 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
WO2018009700A1 (en) * 2016-07-06 2018-01-11 Waters Technologies Corporation Monitoring radiation exposure and radiosensitivity using ambient ionization mass spectrometry
RU2734243C1 (ru) * 2019-07-23 2020-10-13 федеральное государственное бюджетное научное учреждение "Федеральный центр токсикологической, радиационной и биологической безопасности" (ФГБНУ "ФЦТРБ-ВНИВИ") Способ лечения радиационных поражений организма
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69782A (en) * 1982-09-22 1987-12-20 Sentrachem Ltd Compositions for preventing cancerous conditions comprising precursors of eicosanoid mixtures and a dietary supplement containing them
GB8522670D0 (en) * 1985-09-13 1985-10-16 Efamol Ltd Drug treatments
EP0278809B1 (fr) * 1987-01-19 1992-03-25 Parfums Rochas Nouvelles compositions cosmétiques ou dermatologiques renfermant un extrait des fruits de Silybum Marianum riche en Silymarine associé à des acides gras essentiels
ES2040847T3 (es) * 1987-04-27 1996-07-16 Efamol Holdings Un procedimiento para preparar una composicion farmaceutica que contiene una sal de litio.
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5059622A (en) * 1989-08-29 1991-10-22 Biosyn, Inc. Method for reducing blood pressure levels in hypertensive persons
GB8920228D0 (en) * 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
US5271925A (en) * 1990-03-09 1993-12-21 Benjamin Sredni Method for protecting against the effects of radiation which is based on the administration of a selenium or tellurium based compound

Also Published As

Publication number Publication date
AU673868B2 (en) 1996-11-28
ZA94392B (en) 1994-09-01
NZ250757A (en) 1997-06-24
US5583159A (en) 1996-12-10
GB9301446D0 (en) 1993-03-17
CA2114047A1 (en) 1994-07-27
RU94002337A (ru) 1996-08-27
KR940018089A (ko) 1994-08-16
JPH06279277A (ja) 1994-10-04
NO940266D0 (no) 1994-01-25
AU5395894A (en) 1994-08-04
US5663202A (en) 1997-09-02
EP0609064A1 (en) 1994-08-03
CN1104496A (zh) 1995-07-05

Similar Documents

Publication Publication Date Title
NO940266L (no) Indre strålingsskade
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
AU610036B2 (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis inflammation and as immunosuppressants
HK56897A (en) Benzocyclobutyl-or indanyl-alkyl-amino-alkyl substituted 3-benzazepin-2-ones useful in the treatment of cardiovascular diseases
NO982310L (no) Protegriner
DE59509751D1 (de) Gegen hautalterung wirksame stoffe oder wirkstoffkombinationen und zubereitungen
RU93048466A (ru) Применение бензотиофенов для профилактики и лечения остеопороза и фармацевтическая композиция на их основе
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
BG101284A (en) Compounds and methods for cancer treatment
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
NO951240L (no) Anvendelse av IL-10 til forebyggelse eller behandling av insulinavhengig diabetes mellitus
AU2861389A (en) Disubstituted pyridines
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
NO982582L (no) Fremgangsmaate for behandling av smerte
DE69220939D1 (de) Gegengift immunsera
NO940400L (no) Farmasöytisk preparat inneholdene karbakol og andre kolinergiske stoffer
MX9201258A (es) Compuestos para el tratamiento del cancer y procedimiento para su preparacion.
IL89901A0 (en) Strobilurine derivatives
RO103683A2 (en) Treatment medicine for eczema
AU1162592A (en) Low-molecular sulphated poly-beta -2,6-fructofuranosanes and their use in the treatment of degenerative articular ailments
EP0663211A4 (en) AGENT FOR PREVENTION AND TREATMENT OF DIGESTIVE APPARATUS MUCOUS DISORDERS.